Science

AddToAny

Google+ Facebook Twitter Twitter

Some personal thoughts on travel

We asked biomedical scientist and intrepid traveller Sue Alexander her plans and opinions on travel as the world starts to open up again. Here’s what she said.

I have travelled extensively throughout my life, including remote destinations such as The Galapagos, Easter Island, Madagascar and Greenland, as well as more mainstream destinations around the world. Some readers may remember articles in The Biomedical Scientist about my travel to Antarctica and Svalbard. There is no, or very limited access to, medical care in these areas and you have to accept that if you are taken ill in this sort of destination it will take a long time to get you back to safety and you have to bear this in mind. I have also travelled in politically volatile countries and others where kidnapping of tourists is not unknown. I travelled to Europe three times last summer and autumn and have three trips booked this year with further plans. Eventually, I think we will travel as we did before, more or less, but that will take time.

Precautions taken

With two doses of Pfizer and no risk factors, I am not worried myself about travelling, but then I am open to risk. I am also desperate for a “real” break away from work and familiar surroundings so I can totally relax and recharge my batteries. Then there is the traffic light list of countries meaning the choice of destinations is extremely limited, unless you want to isolate on your return, and several of the countries will require you to isolate for up to 14 days on arrival – not inviting. The precautions at airports and on planes are extensive with one-way systems, mask wearing and hand hygiene to the fore. The biggest nightmare has actually been trying to book a COVID PCR test online: the Boots website (other testers are available) is possibly the most labyrinthine I have ever encountered and it took two hours to book two tests. Anyone travelling from the UK to green list countries will almost certainly have had to test negative.

Please click here to read the full article.

Image Credit | Shutterstock

Related Articles

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research-CREDIT_istock-1293772951

Equity, diversity and inclusion for all

Jemma Shead, a Senior Biomedical Scientist at Synnovis and IBMS EDI Working Group member, on how and why you should get involved with EDI.

adeno associated virus capsid-Image Credit | Science Photo Library - c0142837

Examining the medical mystery of child hepatitis outbreak

A study has shed light on an unexpected wave of severe acute hepatitis cases in 2022, amid the backdrop of the ongoing global COVID-19 pandemic.

clostridioides difficile bacteria-Image Credit | Science Photo Library - c0016337

Faecal microbiota transplant for C. diff

In the first comprehensive US evidence-based guideline on the use of faecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends faecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

pseudomonas aeruginosa bacteria Image-Credit | Science Photo Library - f0381226

Tackling priority pathogen with phages

A new study describes the use of phage therapy to eradicate multidrug-resistant Pseudomonas aeruginosa infections in vivo with important new implications for antibiotic resistance.

Top